Medinotec Inc. Reports 79.3% Revenue Growth to $3.24 Million in Latest Quarter

Medinotec Inc. reported significant financial growth in its latest 10-Q filing for the period ending August 31, 2025. The company achieved revenues of $3.24 million for the three months ended August 31, 2025, a 79.3% increase from $1.80 million in the same period last year. For the six months, revenues rose to $5.37 million, up from $3.06 million, marking a 75.5% increase year-over-year. The gross profit for the quarter was $2.00 million, compared to $833,412 in the prior year, while net income for the quarter was $346,566, up from $284,749 in the same quarter of 2024.

The financial performance reflects a notable shift in the company's operational strategy, particularly in its revenue generation from distribution agreements, which accounted for 86.3% of total revenue in the latest quarter. This is an increase from 75.5% in the same quarter of the previous year. The company also reported a significant increase in operating expenses, which rose to $1.47 million for the three months ended August 31, 2025, compared to $397,665 in the same period last year, primarily due to increased sales and marketing efforts and general administrative expenses.

Medinotec has made strategic moves to enhance its market presence, including the establishment of Medinotec Capital Proprietary Limited as a wholly owned subsidiary in South Africa, which acquired DISA Medinotec Proprietary Limited in March 2022. The company is actively pursuing opportunities to expand its sales and distribution operations in the U.S. market, following FDA 510(k) approval for its flagship product, the Trachealator, in November 2021. This product is expected to play a crucial role in diversifying revenue streams and enhancing the company's market share.

Operationally, Medinotec reported a decrease in cash and cash equivalents to $2.25 million as of August 31, 2025, down from $2.77 million at the end of February 2025. The company’s total assets also decreased to $6.37 million from $6.81 million during the same period. The accounts receivable increased slightly to $2.58 million, while inventory rose to $994,074, indicating a focus on maintaining adequate stock levels to support sales growth. The company’s employee headcount remains stable, supporting its operational needs as it continues to expand.

Looking ahead, Medinotec Inc. aims to leverage its recent growth and strategic developments to further penetrate the U.S. market while solidifying its position in South Africa. The company is focused on enhancing its product offerings and expanding its customer base, particularly through its distribution agreements. Management remains optimistic about future revenue growth, driven by increased product adoption rates and geographic expansion efforts.